Steven Pipe, MD
Pediatric Hematology-Oncology · Ann Arbor, MINPI 1255341889
Payments from drug & device makers
Across 1,186 payments — averaging $2986.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$581K
- Genentech, Inc.$486K
- Biomarin Pharmaceutical Inc.$475K
- Sanofi$357K
- Regeneron$248K
- Sanofi US Services Inc.$182K
- plus $1.2M from 21 others
Across 77 payments — averaging $1303.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$76K
- Regeneron$14K
- Sanofi$10K
- Bioverativ Therapeutics Inc.$648
- Pfizer$330
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 294 | $580,987 |
| Genentech, Inc. | 67 | $485,854 |
| Biomarin Pharmaceutical Inc. | 135 | $474,849 |
| Sanofi | 96 | $357,197 |
| Regeneron | 75 | $247,965 |
| Sanofi US Services Inc. | 29 | $181,858 |
| Siemens Medical Solutions USA, Inc. | 24 | $148,179 |
| HEMA Biologics, LLC | 137 | $141,868 |
| Bayer | 21 | $124,531 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $121,605 |
| Bioverativ Therapeutics Inc. | 46 | $104,508 |
| Novo Nordisk | 30 | $73,837 |
| Pfizer | 41 | $72,836 |
| Novo Nordisk AS | 10 | $61,112 |
| Ultragenyx Pharmaceutical Inc. | 17 | $49,698 |
| Novo Nordisk Health Care AG | 14 | $45,428 |
| Spark Therapeutics, Inc. | 14 | $44,734 |
| Roche Products Limited | 14 | $41,785 |
| Genentech USA, Inc. | 52 | $37,515 |
| Sanofi-aventis U.S. LLC | 9 | $36,495 |
| Chugai Pharmaceutical Co., Ltd. | 12 | $34,668 |
| F. Hoffmann-la Roche AG | 22 | $25,884 |
| Hoffmann-la Roche Limited | 6 | $16,553 |
| Alnylam Pharmaceuticals Inc. | 3 | $13,979 |
| Swedish Orphan Biovitrum AB | 2 | $9,900 |
| Samsung Bioepis Co., Ltd. | 2 | $4,000 |
| Shire North American Group Inc | 1 | $3,938 |
How this compares
$3,541,764 in reported general payments places this provider in the 95th percentile of 84 pediatric hematology-oncology providers in Michigan.
See all pediatric hematology-oncology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pediatric hematology-oncology in Ann Arbor
- Santhosh UpadhyayaAnn Arbor$3.9M
- Rajen ModyAnn Arbor$2.5M
- Andrew CampbellAnn Arbor$2M
- Patrick GroharAnn Arbor$1.6M
- Angela WeyandAnn Arbor$1.1M
- Kelly WalkovichAnn Arbor$824K
- Gregory YanikAnn Arbor$553K
- Andrea FransonAnn Arbor$437K
- Ghada AbusinAnn Arbor$399K
- Carl KoschmannAnn Arbor$398K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.